← Back

Wire · opportunities

Abbott kicks off new research on software-guided, balloon-expandable TAVR system

Published

19 November 2026

Topic

opportunities

◆ Sectors

Medtech

◆ Geography

Europe

◆ Source

Read at cardiovascularbusiness.com →

◆ Verified

Fusion42 · 19 November 2026 · Fusion42 review

Abbott has begun a new clinical trial for its software-guided, balloon-expandable Encantor TAVR system targeting patients with large aortic annulus, aiming for CE mark approval in Europe and Australia. The investigational device builds on Abbott's existing TAVR platform and features software-enhanced deployment to improve precision and coronary access.

This Wire brief sits within Fusion42's coverage of Medtech, and 3 sources have reported it between 19 Nov 2026 and 20 Nov 2026.

◆ ◆ The Wire takeaway

You can now explore software-guided balloon-expandable TAVR options as Abbott advances this investigational device toward European approval. This opens doors for newer structural heart devices with precision deployment in your treatment portfolio.

◆ Coverage

3 sources · first reported 19 Nov 2026 · latest 20 Nov 2026

◆ Related on Wire

◆ Topics

Medtechtavrmedtechclinical-trialcardiovascularsoftware-guided